Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 4Inflammation 2Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Skin Diseases 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Rare Diseases 1Pulmonary Arterial Hypertension 1Pneumonia 1Pain 1Neutropenia 1Migraine Disorders 1Metabolic Syndrome 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Intraabdominal Infections 1Influenza, Human 1Infections 1Hypokalemia 1Hypertension 1Hyperandrogenism 1Hyperaldosteronism 1

Interventions

Gemcitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3Ocoxin 2Metformin 2Clomiphene 2relacorilant 1pralsetinib 1pembrolizumab 1parathyroid hormone-related peptide (1-36) 1niraparib 1napabucasin 1Spironolactone 1Paclitaxel 1Octreotide 1Leuprolide 1Irinotecan 1Immune Checkpoint Inhibitors 1Filgrastim 1Eating 1Cisplatin 1Chorionic Gonadotropin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Endocrine System Diseases × Spironolactone × Clear all
NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡